B2i Digital Named Marketing Partner for the Jones Healthcare and Technology Innovation Conference
B2i Digital will showcase profiles of participating companies and sponsors to its community of over 1.2 million influencers in the US Capital Markets
The Jones Healthcare and Technology conference is being held April 8-9, 2025, in Las Vegas, connecting leading innovators, investors, and industry experts
NEW YORK - February 24, 2025 ( NEWMEDIAWIRE) - B2i Digital, Inc., a leading digital marketing firm, has been named Marketing Partner for the Jones Healthcare and Technology Innovation Conference, taking place April 8-9, 2025, at The Venetian Resort in Las Vegas, Nevada. The conference will bring together institutional investors, corporate leaders, and key opinion leaders to explore the latest advancements shaping healthcare and technology.
Featuring thematic panel discussions, corporate presentations, fireside chats with industry leaders, one-on-one meetings, and social events, this special gathering will foster high-level engagement and strategic partnerships. The conference will highlight emerging trends, innovations, and top emerging healthcare and technology companies.
Alan Hill, Chief Executive Officer of Jones, stated, 'Bringing together a highly targeted audience of top emerging Healthcare and Technology companies, institutional investors, as well as distinguished key opinion leaders in both industries is an exciting opportunity for all participants. This conference provides a platform for thought-provoking discussions to drive progress across both sectors.'
David Shapiro, Chief Executive Officer of B2i Digital, commented, 'We are genuinely pleased to welcome the Jones Healthcare and Technology Innovation Conference to our platform as a B2i Digital Featured Conference. We will showcase innovative companies shaping the future of healthcare and technology to our active investor community before, during, and after the event. We will also recognize the hard work of the sponsors who support and advise the participating companies as they navigate the intricacies of the US markets.'
The event will feature keynote addresses from Eric F. Trump, Executive Vice President of the Trump Organization, and Dr. Charity Dean, CEO, Founder, and Chairman of PHC Global, a biosecurity software platform. Attendees will have the opportunity to engage directly with senior executives from innovative companies and gain insights into the latest market trends.
As the conference's official marketing partner, B2i Digital will manage marketing initiatives, including digital company profiles, social media campaigns, and targeted email outreach, to enhance engagement and visibility for presenting companies and conference sponsors.
B2i Digital, Inc. is not an affiliate of JonesTrading and does not represent JonesTrading in any capacity. Content posted on B2i Digital's website was provided and approved by respective companies or available in the public domain.
About B2i Digital, Inc.
B2i Digital, Inc. leverages the latest digital marketing technologies to tell a company's story to retail investors, institutional investors, and research analysts. B2i Digital creates robust profiles for companies on its platform, b2idigital.com, and launches targeted digital marketing campaigns to bring the most relevant investors to each company based on its sector, stage in its capital markets evolution, and overall company story. The company was founded in 2021 by David Shapiro, previously the Chief Marketing Officer for Maxim Group LLC and its investor awareness platform, M-Vest.com.
B2i Digital Contact Information:
David Shapiro
Chief Executive Officer
B2i Digital, Inc.
212.579.4844 Office
212.579.4844 Office
[email protected]
https://www.linkedin.com/company/b2i-digital
https://www.youtube.com/@b2idigital
https://stocktwits.com/B2iDigital
https://www.reddit.com/user/b2idigital/
https://www.pinterest.com/b2idigital/
https://www.tiktok.com/@b2idigital
https://www.threads.net/@b2i_digital
https://bsky.app/profile/b2idigital.bsky.social
About JonesTrading
JonesTrading Institutional Services, LLC ('Jones') is a leading full-service investment banking firm, providing a comprehensive suite of services, including capital markets, M&A, and strategic advisory to corporate clients. The firm is dedicated to building lasting partnerships by delivering innovative solutions, deep industry expertise, and tailored strategies that drive value and success. Founded in 1975, Jones has established itself as the global leader in block trading and a premier liquidity provider to institutional investors. The firm's offerings also include derivatives trading, outsourced trading, electronic trading, prime services, private markets trading, and research/market intelligence. Member FINRA and SIPC.
JonesTrading Contact:
Megan Doyle
VP Corporate Access
325 Hudson Street
New York, NY 10013
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
21 minutes ago
- Yahoo
Babcock & Wilcox Enterprises Insiders Up US$1.1m On US$885.7k Investment
Insiders who purchased Babcock & Wilcox Enterprises, Inc. (NYSE:BW) shares in the past 12 months are unlikely to be deeply impacted by the stock's 10% decline over the past week. After taking the recent loss into consideration, the US$885.7k worth of stock they bought is now worth US$2.00m, indicating that their investment yielded a positive return. Although we don't think shareholders should simply follow insider transactions, we would consider it foolish to ignore insider transactions altogether. AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early. Over the last year, we can see that the biggest insider purchase was by insider Bruce Galloway for US$886k worth of shares, at about US$0.80 per share. We do like to see buying, but this purchase was made at well below the current price of US$1.05. Because it occurred at a lower valuation, it doesn't tell us much about whether insiders might find today's price attractive. The chart below shows insider transactions (by companies and individuals) over the last year. If you click on the chart, you can see all the individual transactions, including the share price, individual, and the date! Check out our latest analysis for Babcock & Wilcox Enterprises Babcock & Wilcox Enterprises is not the only stock insiders are buying. So take a peek at this free list of under-the-radar companies with insider buying. Another way to test the alignment between the leaders of a company and other shareholders is to look at how many shares they own. We usually like to see fairly high levels of insider ownership. Insiders own 10% of Babcock & Wilcox Enterprises shares, worth about US$11m. This level of insider ownership is good but just short of being particularly stand-out. It certainly does suggest a reasonable degree of alignment. It's certainly positive to see the recent insider purchase. And the longer term insider transactions also give us confidence. But on the other hand, the company made a loss during the last year, which makes us a little cautious. Given that insiders also own a fair bit of Babcock & Wilcox Enterprises we think they are probably pretty confident of a bright future. So while it's helpful to know what insiders are doing in terms of buying or selling, it's also helpful to know the risks that a particular company is facing. Be aware that Babcock & Wilcox Enterprises is showing 4 warning signs in our investment analysis, and 2 of those don't sit too well with us... Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of interesting companies. For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Yahoo
26 minutes ago
- Yahoo
IMUNON Announces PlaCCine® DNA Vaccine Technology Abstract Selected for Oral Presentation at 10th International Conference on Vaccines Research & Development™
Clinical Data Highlight PlaCCine's Six-Month Durability, Temperature Stability, and Manufacturing Advantages Over mRNA Vaccines IMUNON Seeks Strategic Partner for PlaCCine® to Advance Novel Technology and Fund Core Pipeline with Non-Dilutive Capital LAWRENCEVILLE, N.J., June 17, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company focused on developing non-viral DNA-mediated immunotherapies and evaluating an adaptation of the platform's potential as a next-generation vaccine, today announced that an abstract highlighting Phase 1 proof-of-concept clinical trial results of IMNN-101, an investigational DNA plasmid vaccine based on the Company's proprietary PlaCCine® technology platform, was accepted for oral presentation at the 10th International Conference on Vaccines Research & Development. The meeting is being held November 5-7, 2025, in Boston, MA. In the Phase 1 trial, designed to demonstrate the potential of IMUNON's technology as a viable alternative to current vaccines including approved messenger RNA (mRNA) vaccines, IMNN-101 was administered as a single dose vaccine without a booster dose in study participants who were previously vaccinated against the Omicron XBB1.5 variant. Study participants had high baseline immune characteristics, presumably from prior infection and/or multiple previous vaccinations against COVID-19, and ongoing infection. Modest increases in T-cell responses were seen in trial participants who received multiple immunizations before the study. In May 2025, IMUNON announced positive six-month data from the Phase 1 trial demonstrating better durability of protection compared to mRNA vaccines after a single dose targeting the SARS-CoV-2 Omicron XBB1.5 spike antigen variant. Results also showed IMNN-101 induced up to a 3-fold median increase in the serum neutralizing antibody (NAb) titers from baseline at six months, with initial evidence of a stronger immune response in the two higher dose cohorts (2.0 mg and 1.0 mg) compared to the lower dose cohort (0.5 mg). IMNN-101 was shown to be safe and well tolerated, with no serious adverse effects reported. 'We are pleased to have the opportunity to present data from the Phase 1 study of IMNN-101 in an oral presentation at one of the leading global vaccine conferences,' said Stacy Lindborg, Ph.D., president and chief executive officer of IMUNON. 'We look forward to sharing with the scientific community our promising results that indicate that our PlaCCine technology platform may support development of vaccines for COVID-19 and emerging pathogens with several competitive advantages, including better durability of protection, vaccine stability at workable temperatures, and ease of manufacturing compared to current mRNA vaccines or traditional vaccines. This recognition underscores the significant potential of PlaCCine as we actively look to partner with strategic partners to help advance this innovative technology as efficiently as possible for protection against infectious agents.' About PlaCCine® and IMNN-101 IMNN-101 utilizes the Company's PlaCCine® technology platform, a proprietary composition of a DNA plasmid that regulates the expression of key pathogen antigens and a novel synthetic DNA delivery system. The plasmid-based expression vector accommodates single or multiple antigens through its flexible vector design, offers manufacturing flexibility compared to viral, mRNA or protein vaccines, and the synthetic delivery system protects DNA from degradation and facilitates DNA uptake after injection with acceptable safety. About the Phase 1 PoC Clinical Trial This U.S. Phase 1 proof-of-concept (PoC) study enrolled 24 participants to evaluate three escalating doses of IMNN-101 with eight participants at each dose. All participants were treated at DM Clinical Research in Philadelphia. For this study, IMNN-101 has been designed to protect against the SARS-CoV-2 Omicron XBB1.5 variant, in accordance with the FDA's Vaccines and Related Biological Products Advisory Committee's June 2023 announcement of the framework for updated COVID-19 doses. The primary objectives of the study are to evaluate safety and tolerability in healthy adults. Secondary objectives include evaluating IMNN-101's immunogenicity and associated durability. About IMUNON IMUNON is a clinical-stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the body's natural mechanisms to generate safe, effective and durable responses across a broad array of human diseases, constituting a differentiating approach from conventional therapies. IMUNON is developing its non-viral DNA technology across its modalities. The first modality, TheraPlas®, is developed for the gene-based delivery of cytokines and other therapeutic proteins in the treatment of solid tumors where an immunological approach is deemed promising. The second modality, PlaCCine®, is developed for the gene delivery of viral antigens that can elicit a strong immunological response. The Company's lead clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer that has completed multiple clinical trials including one Phase 2 clinical trial (OVATION 2). IMNN-001 works by instructing the body to produce safe and durable levels of powerful cancer-fighting molecules, such as interleukin-12 and interferon gamma, at the tumor site. Additionally, the Company has completed its first-in-human study of its COVID-19 booster vaccine (IMNN-101). The Company will continue to leverage these modalities and to advance, either directly or through partnership, the technological frontier of plasmid DNA to better serve patients with difficult-to-treat conditions. For more information, please visit Forward-Looking Statements IMUNON wishes to inform readers that forward-looking statements in this news release are made pursuant to the 'safe harbor' provisions of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, including, but not limited to, statements regarding the timing of enrollment of the Company's clinical trials, the potential of any therapies developed by the Company to fulfill unmet medical needs, the market potential for the Company's products, if approved, the potential efficacy and safety profile of our product candidates, and the Company's plans and expectations with respect to its development programs and potential partnerships more generally, are forward-looking statements. We generally identify forward-looking statements by using words such as 'may,' 'will,' 'expect,' 'plan,' 'anticipate,' 'estimate,' 'intend' and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances). Readers are cautioned that such forward-looking statements involve risks and uncertainties including, without limitation, uncertainties relating to unforeseen changes in the course of research and development activities and in clinical trials, including the fact that interim results are not necessarily indicative of final results; the uncertainties of and difficulties in analyzing interim clinical data; the significant expense, time and risk of failure in conducting clinical trials; the need for IMUNON to evaluate its future development plans; possible actions by customers, suppliers, competitors or regulatory authorities; and other risks detailed from time to time in IMUNON's filings with the Securities and Exchange Commission. IMUNON assumes no obligation, except to the extent required by law, to update or supplement forward-looking statements that become untrue because of subsequent events, new information or otherwise. Contacts: Media Investors Jenna Urban Peter Vozzo CG life ICR Healthcare 212-253-8881 443-213-0505 jurban@ in to access your portfolio
Yahoo
39 minutes ago
- Yahoo
BioRestorative Announces Share Repurchase Program
MELVILLE, N.Y., June 17, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ('BioRestorative', 'BRTX' or the 'Company') (NASDAQ:BRTX), a clinical stage regenerative medicine innovator focused on stem cell-based therapies and products, today announced that its Board of Directors has authorized a stock repurchase program under which the Company may repurchase up to $2 million of its outstanding common stock through June 16, 2026. "This share repurchase program reflects our confidence in the strength of our clinical development pipeline and the future outlook of our business,' said Lance Alstodt, Chief Executive Officer of BioRestorative. 'There is no question in our minds that BioRestorative has great science, assets and people. As such, we believe our current share price does not reflect the intrinsic value of the company, particularly in light of our recent clinical and operational progress. Accordingly, we believe this program provides us with an opportunity to enhance long-term shareholder value.' The repurchases may be made from time to time in the open market, through privately negotiated transactions, or by other means in accordance with applicable securities laws. The timing, number, and value of shares repurchased under the program will be at the discretion of the Company's management and will depend on a variety of factors, including market conditions, share price, and other corporate considerations. The share repurchase program may be modified, suspended or terminated at any time at the Company's discretion and does not obligate the Company to acquire any amount of common stock. About BioRestorative Therapies, Inc. BioRestorative ( develops therapeutic products using cell and tissue protocols, primarily involving adult stem cells. As described below, our two core clinical development programs relate to the treatment of disc/spine disease and metabolic disorders, and we also operate a commercial BioCosmeceutical platform: • Disc/Spine Program (brtxDISC™): Our lead cell therapy candidate, BRTX-100, is a product formulated from autologous (or a person's own) cultured mesenchymal stem cells collected from the patient's bone marrow. We intend that the product will be used for the non-surgical treatment of painful lumbosacral disc disorders or as a complementary therapeutic to a surgical procedure. The BRTX-100 production process utilizes proprietary technology and involves collecting a patient's bone marrow, isolating and culturing stem cells from the bone marrow and cryopreserving the cells. In an outpatient procedure, BRTX-100 is to be injected by a physician into the patient's damaged disc. The treatment is intended for patients whose pain has not been alleviated by non-invasive procedures and who potentially face the prospect of surgery. We have commenced a Phase 2 clinical trial using BRTX-100 to treat chronic lower back pain arising from degenerative disc disease. We have also obtained U.S. Food and Drug Administration ('FDA') Investigational New Drug ('IND') clearance to evaluate BRTX-100 in the treatment of chronic cervical discogenic pain. • Metabolic Program (ThermoStem®): We are developing cell-based therapy candidates to target obesity and metabolic disorders using brown adipose (fat) derived stem cells ('BADSC') to generate brown adipose tissue ('BAT'), as well as exosomes secreted by BADSC. BAT is intended to mimic naturally occurring brown adipose depots that regulate metabolic homeostasis in humans. Initial preclinical research indicates that increased amounts of brown fat in animals may be responsible for additional caloric burning as well as reduced glucose and lipid levels. Researchers have found that people with higher levels of brown fat may have a reduced risk for obesity and diabetes. BADSC secreted exosomes may also impact weight loss. • BioCosmeceuticals: We operate a commercial BioCosmeceutical platform. Our current commercial product, formulated and manufactured using our cGMP ISO-7 certified clean room, is a cell-based secretome containing exosomes, proteins and growth factors. This proprietary biologic serum has been specifically engineered by us to reduce the appearance of fine lines and wrinkles and bring forth other areas of cosmetic effectiveness. Moving forward, we also intend to explore the potential of expanding our commercial offering to include a broader family of cell-based biologic aesthetic products and therapeutics via IND-enabling studies, with the aim of pioneering FDA approvals in the emerging BioCosmeceuticals space. Forward-Looking Statements This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events or results to differ materially from those projected in the forward-looking statements as a result of various factors and other risks, including, without limitation, those set forth in the Company's latest Form 10-K, filed with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and the Company undertakes no obligation to update such statements. CONTACT: Stephen KilmerInvestor RelationsDirect: (646) 274-3580 Email: skilmer@
